Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Procaine→

Procaine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59-46-1
Molecular formula
C13H20N2O2
Molecular weight
236.31 g/mol
Drug class
Ester-type local anaestheticpara-aminobenzoic acid derivative
Mechanism of action
Blocks voltage-gated sodium channels in neuronal membranes, preventing initiation and conduction of nerve impulses and producing reversible local anaesthesia. It is hydrolysed by plasma esterases to para-aminobenzoic acid and diethylaminoethanol.
Indications / reported uses
  • Local anaesthesia for infiltration and selected regional anaesthetic procedures using authorised injectable formulations; current use is limited in many jurisdictions because of shorter duration and availability of alternative local anaesthetics

Sources: NLM MeSH — Procaine · PubMed — Procaine local anaesthetic mechanism · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ester-type local anaesthetic; para-aminobenzoic acid derivative

Mechanism of action

Blocks voltage-gated sodium channels in neuronal membranes, preventing initiation and conduction of nerve impulses and producing reversible local anaesthesia. It is hydrolysed by plasma esterases to para-aminobenzoic acid and diethylaminoethanol.

General use cases

  • Local anaesthesia for infiltration and selected regional anaesthetic procedures using authorised injectable formulations; current use is limited in many jurisdictions because of shorter duration and availability of alternative local anaesthetics

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Procaine Environmental Risk Assessment (ERA) (the Procaine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.